Sulfonylureas
Common brand names: Glipizide, Glimepiride, Glyburide
One nutrient listed against this medication. The most severe is marked mild.
At a glance
At a glance
- CoQ10Mild · Mechanism only, no human trial
Color shows how serious each listed effect is. The label beside it shows how strong the evidence is. The cards below explain each one and show its evidence.
Nutrients it can lower
Mechanism, Sulfonylureas suppress ATP-sensitive potassium channels in pancreatic cells, a mechanism that intersects with CoQ10-dependent mitochondrial energy pathways.
Common signs, Fatigue, reduced exercise tolerance, cardiovascular risk
Kishi et al. (J Med, 1976; PMID PubMed ID: the permanent number the US National Library of Medicine gives a published paper. Each one links to that paper's record on PubMed. 1070515): measured CoQ10-enzyme inhibition across seven antidiabetic drugs. Acetohexamide, glyburide, phenformin and tolazamide inhibited NADH-oxidase; glipizide, tolbutamide and chlorpropamide did not. The depletion signal in this class does not extend to glipizide itself.
CoQ10 100–200 mg daily is a range in common use, not from a trial cited on this row.
For your next appointment
It prints or saves as a single page. Whether to add a supplement for a nutrient this medication may lower is a decision for your prescriber.
Disclosure
These statements have not been evaluated by the Food and Drug Administration. Any grade on this page describes the strength of published human trial evidence in the populations studied. It is not a recommendation for any individual and is not medical advice. Starting, stopping or changing any supplement or medication is a decision for your physician.
Grades move when new trials publish. A free monthly email lists every grade EBL moved, with the reason and the trial behind it: the sign-up is on the Evidence Log →